Navigation Links
AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board
Date:11/8/2011

us to all parties immediately, that there is a common understanding what the future development of AFFiRiS should look like as we implement the appropriate actions. We are delighted that Santo is appreciating AFFiRiS's potential by committing a substantial stake into the company."

Opportunities > Risks

Regarding his positive investment decision for AFFiRiS, Thomas Strüngmann explains: "We are excited about the opportunity to invest into this very promising biotech company. Seeing what Walter Schmidt and Frank Mattner have created and established with their top class team we remain highly impressed."

A further substantial argument for Santo to invest into AFFiRiS is related to recent developments in its key projects - in particular to the exciting progress of the ongoing Parkinson's project. Here, the aim is to deliver the world's first vaccine for Parkinson's disease - a project for which a Phase I safety and tolerability trial, supported by the American Michael J. Fox Foundation with almost USD 2 million, will start early 2012.The Parkinson's disease vaccine benefits from the company's experience in developing vaccines against Alzheimer's disease. In 2008, the company closed a licence agreement with GSK Biologicals, worth up to EUR 430 Mio. milestone-based payments.  

The basis for all these programmes is the company's AFFITOME® technology plus related know-how which allows the preclinical development of entire vaccine families with high specificity which are then moved quickly into clinical testing following the company's strategy called "clinical maturation".

Michael Motschmann, Management Chairman of the board of MIG Verwaltungs AG, on the most recent company developments: "AFFiRiS is an incredibly attractive investment. The company offers the unique combination of a validated platform technology and an approach of producing several vaccine candidates respectively, for diseases with unmet medical need and attr
'/>"/>

SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
5. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
6. AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
7. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
8. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
9. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
10. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
11. Aegis Analytical Corp. Showcases Discoverant at Inaugural Venture Capital in the Rockies Fall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 Semiconductor industry leader ... Light-based Technologies (IYL 2015) visionary John Dudley were ... the international society for optics and photonics , last ... and Dudley along with other awards announced earlier this ... by James Harrington, during a gala banquet Wednesday evening ...
(Date:9/2/2014)... detailed studies of what happens on the surface of ... other applications. A group of researchers from Lund University ... form across a large number of vertical nanowires, known ... of a cell and its surroundings takes place through ... that holds the cell together and that largely comprises ...
(Date:9/2/2014)... 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") today ... for protecting personal data in Clinical Study Reports ... others. The document describes an approach to apply ... and other related clinical trial documents, and is ... of the TransCelerate CSR Redaction approach is to ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014 ... announced that the U.S. Patent and Trademark Office (PTO) ... investigational medication being evaluated for weight loss. NB32 is ... bupropion SR. U.S. Patent No. 8,815,889 claims ... naltrexone and bupropion. The patent expires in 2024. If ...
Breaking Biology Technology:Levinson, Dudley Win SPIE Directors’ and President’s Awards 2Levinson, Dudley Win SPIE Directors’ and President’s Awards 3Levinson, Dudley Win SPIE Directors’ and President’s Awards 4Nano-forests to reveal secrets of cells 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... Lumiphore, Inc., a,biotechnology leader in the ... use in high-value applications, announced,that it has ... Inc.,Redwood City, California to apply Lumiphore products ... Under the agreement, Biophor Diagnostics holds the ...
... Inc. (OTC,Bulletin Board: NZYM) announced today the appointment ... on October 1, 2008. Since May,2008, Dr. Farkas ... over 13 years, experience with amino acid derivatives, ... and supply chain,management at Bachem Corporation, Novartis AG ...
... NxStage Medical,Inc. (Nasdaq: NXTM ), a leading manufacturer ... Chief Executive Officer,and Robert S. Brown, Chief Financial Officer, ... on October 6, 2008 at Le Parker,Meridien Hotel in ... Monday, October 6th at,2:30 p.m. ET. To listen to ...
Cached Biology Technology:Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board 2Synthetech Announces New Director of Manufacturing 2NxStage Medical to Present at JMP Securities Healthcare Focus Conference 2
(Date:9/2/2014)... truth; everyone has a tipping point. We all want to ... benefit is great enough. Now, scientists have confirmed the area ... , The result was published online this week in ... honest, even if lying is beneficial," said Lusha Zhu, the ... Virginia Tech Carilion Research Institute , where she works with ...
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/1/2014)... the U.S. diet showed some modest improvement in the ... in the consumption of unhealthy trans fats, but the ... and the poor. , , An unhealthy diet is ... Eating a healthy diet is an important part of ... trends in diet quality is important because it can ...
Breaking Biology News(10 mins):Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... its prestigious Clinical and Translational Science Award (CTSA) ... the amount of $29 million over the next ... wireless technology and bioinformatics toward individualizing medicine. ... Health and The Scripps Research Institute in partnership ...
... 22, 2013 More accurate and precise assessment of ... a particular gene that are present in a genome, ... cancer and other diseases including autoimmune disorders. However, ... labor intensive, or prohibitively costly, diminishing their effectiveness in ...
... New research shows that in sub-Saharan Africa the virus responsible ... distances and the African buffalo are important natural reservoirs for ... online open-access journal of the American Society for Microbiology, sheds ... 2 emerged in sub-Saharan Africa and identifies patterns of spread ...
Cached Biology News:NIH awards Scripps Translational Science Institute $29 million grant 2NIH awards Scripps Translational Science Institute $29 million grant 3Bio-Rad's Droplet Digital PCR technology highlighted at ASHG Annual Meeting 2Foot and mouth disease in sub-Saharan Africa moves over short distances, wild buffalo are a problem 2
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
...
Biology Products: